SK Biopharm’s Hefty IPO To Support Novel Anti-Epileptic, Pipeline

Bellwether Of Post-COVID Sentiment

 
• By Jung Won Shin
Dollar bills
SK’s Successful IPO To Speed Up Offerings By Other Biotechs

More from South Korea

More from Focus On Asia